Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
STAT1d
Zealand’s obesity strategy and Immunovant’s curious development plan
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
No. 5 / 2025Zealand Pharma increases its share capital as a result of the exercise of employee warrantsCopenhagen, ...
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
STAT9d
Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...
The Manila Times4d
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...
Yahoo Finance10d
Roche secures Zealand obesity drug candidate for up to $5.3 billion
ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects ...
Morningstar5d
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes in the first half of 2025. Copenhagen, Denmark ...